Questions across 3 calls

Sidharth Negandhi

Chanakya Wealth Creation

Mankind Pharma Limited

Mankind Pharma Limited CC-Feb26.pdf · 2026-02-03

I think there has been a fairly good understanding on what transformation has happened on the people front. If I would ask on how do you see the product portfolio to supplement this, right? You highlighted about how you outpaced ex GLP -1 growth. But then GLP-1 is a reality of the future, right? And therefore, in terms of the impact that GLP -1 had on your own existing portfolio? If you could share some color on that and your own plans on launching GLP-1? That was question number one. Question number two, on the acute side of the portfolio, are you seeing the growth being impacted more by trade generics or by loss of share to sort o f other IPM players, how are you seeing that? That's question number two. Question number three, you spoke about e -commerce and modern trade growing about 30%, 40% in OTC. Certain quick commerce players have highlighted the fact that sexual wellness for them has grown multifold sort of upwards of 10 0%. Within this, if you could give some color on how your growth has been and how is share look like for you? And then fourth, you mentioned about the NSP for quick commerce and modern trade being lower than GT . How is the EBITDA profile in that case compared to GT and therefore, how should we think about profitability for that business as these channels sort of gain more salience?

Sure. So just a follow-up on that, you.

Cipla Limited

Cipla Limited CC-Jul25.pdf · 2025-07-25

Just following up on the questions on trade generics. Just wanted to understand, given what you mentioned about a possible sort of impact on the branded generics, what would be the quantum of growth in the trade generics business? And how do you see this g oing forward in context of the overall IPM growth?

Okay. Because -- sir, just a follow-up on that. We've been seeing trade generics grow faster than IPM in the past. And do we believe that given the additional competition that's coming into trade generics, our trade generics business is likely to grow at t hat rate? Or do you see overall trade generics as a space growing at that pace?

Cipla Limited CC-Mar25.pdf · 2025-05-13

This was again on the domestic business. How are you thinking of the schedule extension that was given up to 31st December for MSMEs in context of whether that can be a tailwind for further growth on the trade generics business as well as the branded generics business? Do you see that a tailwind coming in should that implementation happen? And how are you thinking whether that is likely to happen?

And the second question was on what you mentioned about the recent most U.S. regulations, right? Now while it is an advantage for generics as far as the MSME is concerned, given certain parts of the portfolio at supplies, also specialty, does that most favored nation policy create any impact on that specialty part of the portfolio?